Clinical trial

Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )

NCT06939036

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2025-07-01

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2025-07-01Date precision: day

Registry last updated2026-02-05

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Small Cell Lung Cancer Extensive Stageunresolved

Merkel Cell Carcinomaunresolved

Interventions

225Ac-SSO110 + SoCDRUG

AtezolizumabDRUG · verified · RxNorm: atezolizumab

DurvalumabDRUG · verified · RxNorm: durvalumab

AvelumabDRUG · verified · RxNorm: avelumab

PembrolizumabDRUG · verified · RxNorm: pembrolizumab

RetifanlimabDRUG · verified · RxNorm: retifanlimab

Sponsors & collaborators

Ariceum Therapeutics GmbHlead sponsor

Mapped research locations

MiamiFlorida, United States1 PittsburghPennsylvania, United States1 LouisvilleKentucky, United States1 FairfaxVirginia, United States1 HackensackNew Jersey, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06939036 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.